APCS-540, a newly developed inhibitor targeting glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HDACs), inhibited tumor growth and prolonged survival in an ovarian cancer model (108). Here, GSK3B is linked to neoplasm.